H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on Tenaya Therapeutics to $18 from $25 and keeps a Buy rating on the shares following the 2022 results. The analyst says the company continues to progress its three primary assets for those diagnosed with cardiovascular disease.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TNYA:
- Tenaya Therapeutics reports Q4 EPS (61c), consensus (65c)
- Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- 3 Stocks Insiders Love
- Tenaya Therapeutics management to meet virtually with Piper Sandler
- Tenaya Therapeutics to Participate in Upcoming Investor Conferences
